Physician profile
Danny C Chow
NPI 1083613038
$699.60
in general payments reported to CMS, 2019-2025
24 companies · $86.48 in 2025
The $86.48 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $217 · 2020: $170 · 2021: $76.95 · 2022: $22.29 · 2023: $37.42 · 2024: $89.37 · 2025: $86.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $104.88 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $81.35 | 2019-2025 | Rezlidhia, Gavreto, Tavalisse |
| Astellas Pharma US INC | $41.55 | 2019-2020 | |
| Genmab U.S., INC. | $38.67 | 2023-2024 | Tivdak, Epkinly |
| Caris Mpi, INC. | $38.33 | 2025 | Mi Cancer Seek |
| Merck Sharp & Dohme LLC | $34.31 | 2020-2023 | Lynparza, Keytruda |
| Amgen INC. | $31.05 | 2019 | |
| Alexion Pharmaceuticals, INC. | $30.29 | 2024 | Ultomiris |
| Incyte Corporation | $28.04 | 2019-2021 | |
| Beigene USA, INC. | $24.14 | 2021 | |
| Agios Pharmaceuticals, INC. | $23.38 | 2025 | Pyrukynd |
| Celgene Corporation | $23.26 | 2019 | |
| Deciphera Pharmaceuticals INC. | $22.96 | 2021 | |
| Olympus America INC. | $22.46 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.29 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.22 | 2019 | |
| Tersera Therapeutics LLC | $17.15 | 2024 | Xermelo |
| Lilly USA, LLC | $14.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2020 | |
| Dova Pharmaceuticals | $13.96 | 2019 | |
| Eisai INC. | $13.46 | 2020 | |
| Novocure INC. | $12.77 | 2020 | |
| Daiichi Sankyo INC. | $11.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.